Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

Inclusion Criteria: 1. Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 3. Pain score \>/= 4 on a 0-10 numeric pain scale and/or grade 3 neuropathic symptoms according to the National Cancer Institute's 4 point grading scale. 4. Pain must be related to chemotherapy (in the opinion of the treating physician). 5. Patients must have had neuropathic pain for a minimum of 3 months. 6. No plans to change pain medication regimen during the course of the study. 7. Off active chemotherapy treatment for minimum of 3 months. 8. Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.) therapies allowed as long as they will be continued during the course of the study. 9. Willing to come to MD Anderson for the therapy sessions; or willing to participate in the therapy sessions at their homes and live within a 45 minute drive of MDA main campus; or can participate in the therapy sessions from one of MDA's Regional Care Centers. Exclusion Criteria: 1. Patients who are taking any antipsychotic medications. 2. Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy. 3. Patients who have ever been diagnosed with bipolar disorder or schizophrenia.